About IGM Biosciences
IGM Biosciences is a Healthcare company based in Mountain View (United States) founded in 2010, and was acquired by Concentra Biosciences in July 2025. Antibodies for cancer and infectious disease treatments are developed. IGM Biosciences has raised $102.67 million across 3 funding rounds from investors including Haldor Topsoe, Janus Henderson Investors and Redmile Group. The company has 181 employees. Its chief executive, as recorded, is Fred M Schwarzer. IGM Biosciences offers products and services including IgM Antibodies and Antibody Platform. Its focus areas include Life Sciences, Oncology, Drugs and Colorectal Cancer. Its legal entity is IGM Biosciences, Inc. Its competitors include Moderna, Forge Biologics and Dren Bio; 3 of its 3 listed competitors have raised funding.
Company details
IGM Biosciences was founded in 2010 in Mountain View, United States, within the biotechnology sector. Focus is placed on developing IgM and IgA antibodies that target CD20, PD-L1, CTLA-4, and death receptor 5. These antibodies are advanced for treating Non-Hodgkins lymphoma, solid tumors, HIV, and HBV. Operations emphasize immune checkpoint modulation and infectious disease control through clinical-stage programs.
- Headquarters Mountain View, United States
- Employees 181
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website igmbio.com
- Social LinkedIn
- Acquired by Concentra Biosciences (Jul 2025)
- Legal Name Igm Biosciences, Inc.
- Net Profit-$195.8 M (USD)21as on Dec 31, 2024
- EBITDA-$208.58 M (USD)21as on Dec 31, 2024
- Total Equity Funding$102.67M (USD)
in 3 rounds
- Latest Funding Round$120M (USD), Post-IPO
Jul 2023
- InvestorsHaldor Topsoe
& 4 more
- Employee Count181
- Acquired byConcentra Biosciences
(Jul 2025)
Products & Services of IGM Biosciences
IGM Biosciences offers a comprehensive portfolio of products and services, including IgM Antibodies and Antibody Platform.
Engineered for targeting autoimmune and inflammatory diseases effectively.
Platform for developing IgM-based therapeutics for disease treatment.
Funding Insights of IGM Biosciences
IGM Biosciences has successfully raised a total of $102.67M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $120 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $102.67M
- Total Rounds 3
- Last Round Post-IPO — $120M
- First Round $671,417
(Sep 2011)
- Investors Count 4
All 3 funding rounds of IGM Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $120M | Post-IPO | – | – | – |
| Jul 2019 | $102M | Series C | – | Redmile Group, Janus Henderson Investors | |
| Sep 2011 | $671,417 | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in IGM Biosciences
IGM Biosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Haldor Topsoe, Janus Henderson Investors and Redmile Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Catalysts for renewable fuels and green chemicals are supplied. | 2006 | topsoe.com | Lyngby, Denmark | |
Biotechnology firm involved in pharmaceutical acquisitions and industry expansions. | 2023 | concentrabiosciences.com | Canada |
Investor details for IGM Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IGM Biosciences
18 people are tracked at IGM Biosciences (6 in leadership, 10 in board & advisors, 2 in team); the tracked headcount is 181.
| Name | Role | Group |
|---|---|---|
Fred M Schwarzer | CEO | Leadership |
Mary Beth Harler | Chief Executive Officer | Leadership |
Liqin Liu | Sr Director, I-o Research | Leadership |
Lisa L. Decker | Chief Business Officer | Leadership |
Bruce Keyt | Chief Scientific Officer | Leadership |
Carrie Brodmerkel | Chief Scientific Officer, IGM Autoimmunity & Inflammation | Leadership |
Julie Hambleton | Director | Board & advisors |
M. Kathleen Behrens | Director | Board & advisors |
Mark M. Davis | Advisor | Board & advisors |
Michael Lee | Director | Board & advisors |
Felix J. Baker | Director | Board & advisors |
Jakob Haldor Topsøe | Director | Board & advisors |
Christina Teng Topsøe | Director | Board & advisors |
Rafi Ahmed | Advisor | Board & advisors |
Gordon J. Freeman | Advisor | Board & advisors |
Michael Loberg | Chairman | Board & advisors |
Saketh Chemuru | Scientist II | Team |
Adam Shepherd | Clinical Quality Assurance | Team |
Complete people profiles for IGM Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IGM Biosciences
5 dated milestones of IGM Biosciences across 15 years, from founding to its latest funding, stage changes and deals.
- Founded IGM Biosciences is founded.
- Funding First funding round of $671K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $120.0M.
- Exit Acquired by Concentra Biosciences.
Competitors of IGM Biosciences
IGM Biosciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, Forge Biologics and Dren Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| drenbio.com | 2019 | San Carlos, United States | $131M | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. |
Detailed competitors of IGM Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of IGM Biosciences
Websites that share an audience with IGM Biosciences (igmbio.com).
Websites whose visitors overlap most with IGM Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oribiotech.com | 100% | 9.1K | #1,722,992 | View details | |
| trinitybiotech.com | 71% | 9.3K | #2,475,266 | View details | |
| igmfinancial.com | 23% | 14.8K | #1,742,641 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as IGM Biosciences (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Igm Biosciences
Complete news archive for IGM Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IGM Biosciences
IGM Biosciences was founded in 2010 and raised its 1st funding round 1 year after it was founded.
IGM Biosciences is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Fred M Schwarzer is the CEO of IGM Biosciences, as recorded in our data.
IGM Biosciences is a funded company, having raised a total of $102.67M across 3 funding rounds to date. The company's 1st funding round was a Seed of $671.42K, raised on Sep 2011.
IGM Biosciences has 181 employees.
IGM Biosciences was founded in 2010 in Mountain View, United States, within the biotechnology sector. Focus is placed on developing IgM and IgA antibodies that target CD20, PD-L1, CTLA-4, and death receptor 5. These antibodies are advanced for treating Non-Hodgkins lymphoma, solid tumors, HIV, and HBV. Operations emphasize immune checkpoint modulation and infectious disease control through clinical-stage programs.
IGM Biosciences's top competitors include Moderna, Forge Biologics and Dren Bio.
IGM Biosciences offers IgM Antibodies and Antibody Platform.
IGM Biosciences has 5 investors. Key investors include Haldor Topsoe, Janus Henderson Investors, Redmile Group, Vivo Capital, and Concentra Biosciences.
IGM Biosciences operates through Igm Biosciences, Inc..
Yes. IGM Biosciences was acquired by Concentra Biosciences in July 2025.